PLACE OF MANINIL ® IN CURRENT TREATMENT POLICY FOR TYPE 2 DIABETES MELLITUS

Among oral glucose-lowering drugs, glibenclamide (Maninil ®) continues to maintain its leading positions as the most effective hypoglycemic agent. The efficacy of the drug is due to its unique chemical structure that contains not only a sulfonylurea ring, but also a benzamide group in the side chain, which ensures the highest affinity for sulfonylurea (SU) receptor 1 (SUR1) on the β-cells of adenosine phosphate-dependent K + channels, on the one hand, and its ability to bind to SUR2A on the peripheral tissue cells, such as cardiomyocytes, vascular wall smooth muscle cells, and neurocytes, on the other hand. At the same time, this peculiarity can increase the risk of hypoglycemic states and have a negative impact on the cardiovascular system. The data of the clinical trials proving the efficacy and safety of the drug that received the 2010 G.G. Creutzfeldt Drug Prize due to the evidence-based long-term follow-ups demonstrating the reduced risk of vascular complications of diabetes mellitus, its capacity of combining with medicines of other groups, its use in elderly and multimorbid patients. Glibenclamide is the only SU agent entered into the WHO’s list of essential medicines.

therapy for type 2 diabetes mellitus, insulin secretion, sulfonylurea receptor - SUR, K -channels, ischemic preconditioning, hypoglycemic states